KING PHARMACEUTICALS, INC.
As
filed with the Securities and Exchange Commission on September 6, 2005.
Registration No. 333-_________
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
KING PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)
|
|
|
Tennessee
|
|
54-1684963 |
(State or other jurisdiction of
|
|
(I.R.S. Employer |
incorporation or organization)
|
|
Identification No.) |
501 Fifth Street
Bristol, Tennessee 37620
(Address of Principal Executive Offices including zip code)
KING PHARMACEUTICALS, INC. INCENTIVE PLAN
(Full title of the plan)
Brian A. Markison
President and Chief Executive Officer
King Pharmaceuticals, Inc.
501 Fifth Street
Bristol, Tennessee 37620
(423) 989-8000
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copy to:
Jonathan L. Kravetz, Esq.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
One Financial Center
Boston, MA 02111
(617) 542-6000
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proposed maximum |
|
|
Proposed maximum |
|
|
|
|
|
|
|
Title of securities |
|
|
Amount to be |
|
|
|
offering |
|
|
aggregate offering |
|
|
|
Amount of |
|
|
|
to be registered |
|
|
registered |
|
|
|
price per share (1) |
|
|
price(1) |
|
|
|
registration fee |
|
|
|
Common stock,
no par value |
|
|
30,000,000 shares |
|
|
$14.76 |
|
|
$ |
442,800,000 |
|
|
|
$ |
52,117.56 |
|
|
|
Rights to purchase
preferred stock |
|
|
|
(2) |
|
|
|
(2) |
|
|
|
(2) |
|
|
|
None |
|
|
(1) |
|
Estimated solely for the purpose of calculating the registration fee and, pursuant to
paragraphs (c) and (h) of Rule 457 under the Securities Act of 1933, as amended (the
Securities Act), based upon the average of the high and low prices of such common stock as
reported on
the New York Stock Exchange on September 2, 2005 . The maximum number of shares which
may be sold upon the exercise of options or issuance of stock awards granted under the Plan may
be subject to adjustment in accordance with certain anti-dilution and other provisions of the
Plan. Accordingly, pursuant to Rule 416 under the Securities Act, this Registration Statement
covers, in addition to the number of shares stated above, an indeterminate number of shares
which may be subject to grant or otherwise issuable after the operation of any such
anti-dilution and other provisions. |
|
(2) |
|
No separate consideration will be received for the Rights. |
TABLE OF CONTENTS
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
The documents containing the information specified in Part I of this Registration Statement on
Form S-8 will be sent or given to the participants in the plan as specified under Rule 428(b)(1)
under the Securities Act of 1933, as amended (the Securities Act). Such documents are not
required to be, and are not being, filed by King Pharmaceuticals, Inc. (the Company) with the
Securities and Exchange Commission (the Commission), either as part of this Registration
Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities
Act. Such documents, together with the documents incorporated by reference herein pursuant to Item
3 of Part II of this Registration Statement on Form S-8, constitute a prospectus that meets the
requirements of Section 10(a) of the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents By Reference.
The Company has filed the following documents with the Commission and incorporates them herein
by reference:
|
1. |
|
The Companys Annual Report on Form 10-K for the year ended
December 31, 2004, filed with the Commission on March 21, 2005. |
|
|
2. |
|
The Companys Quarterly Report on Form 10-Q for the quarter ended
March 31, 2005, filed with the Commission on May 10, 2005. |
|
|
3. |
|
The Companys Quarterly Report on Form 10-Q for the quarter ended
June 30, 2005, filed with the Commission on August 9, 2005. |
|
|
4. |
|
The Companys Current Reports on Form 8-K filed with the Commission
on March 1, March 21, April 12 (with respect to the disclosure under Item
1.01 only), May 27, and June 6, 2005. |
|
|
5. |
|
The description of the Companys Common Stock contained in the
registration statement on Form 8-A, as filed with the Commission on May 12,
2000, as amended. |
|
|
6. |
|
The description of the Companys Preferred Stock Purchase Rights,
issued under the Rights Agreement by and between the Company and American
Stock Transfer and Trust Company, as Rights Agent, dated as of July 23, 2004,
contained in the registration statement on Form 8-A/A filed with the
Commission on July 26, 2004. |
All reports and other documents subsequently filed by the Company pursuant to Sections 13(a),
13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment
indicating that all securities offered hereby have been sold or deregistering all securities then
remaining unsold shall be deemed to be incorporated herein by reference and to be a part hereof
from the date of the filing of such reports and documents.
Any statement contained in a document incorporated or deemed to be incorporated by reference
herein shall be deemed to be modified or superseded for purposes of this Registration Statement to
the extent that a statement contained herein or in any other subsequently filed document which also
is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any
statement so modified or superseded shall not be deemed, except as so modified or superseded, to
constitute a part of this Registration Statement.
The Company will provide, without charge, to each plan participant a copy of the documents
incorporated by reference in Item 3 of Part II of this Registration Statement, upon written or oral
request. Further, we will provide
2
plan participants, without charge, upon written or oral request, other documents required to
be delivered pursuant to Rule 428(b) under the Securities Act. Written requests should be directed
to King Pharmaceuticals, Inc., Attn: Human Resources, 501 Fifth Street, Bristol, Tennessee, 37620.
Telephone requests may be directed to Human Resources at (423) 989-8000.
Item 4. Description of Securities.
Not applicable.
Item 5. Interests of Named Experts and Counsel.
Not applicable.
Item 6. Indemnification of Directors and Officers.
The Tennessee Business Corporation Act (the Act) provides financial protection by the
Company for its directors, officers and employees against liabilities and expenses (including
attorneys fees, judgments, fines, ERISA excise taxes or penalties and amounts paid in settlement)
incurred by them in proceedings arising out of their position with the Company.
Under the Acts permissive indemnification provisions, a corporation has the authority to
indemnify a director against liability incurred in a proceeding if the director conducted himself
in good faith and in a manner he reasonably believed to be in the corporations best interests. In
the case of criminal proceedings, the director must have no reasonable cause to believe his conduct
was unlawful. Permissive indemnification is allowed even if the director is not wholly successful
in the proceeding. Indemnification is, however, prohibited in derivative actions in which the
director is adjudged liable and in situations in which the director is found liable on the basis
that a personal benefit was improperly received by him. The Act also provides that unless limited
by its charter, a corporation must indemnify a director who is wholly successful on the merits or
otherwise in the defense of a proceeding against reasonable expenses incurred in connection with
the proceeding. In addition to providing indemnification for liabilities for which the director is
held liable, the Act also provides that a corporation may advance expenses incurred by a director
if the director can furnish a written statement of his good faith belief that he acted in an
appropriate manner and undertakes to repay the amount advanced if it is ultimately determined that
he was not entitled to indemnification.
The Act contains provisions extending indemnification to officers, employees and agents of a
corporation. The Act states that a corporation may also indemnify and advance expenses to an
officer, employee or agent who is not a director to the extent consistent with public policy, that
may be provided by its charter, bylaws, general or specific action of its board of directors or
contract.
The Companys Charter and Bylaws provide for indemnification of directors, officers, employees
and agents to the fullest extent allowed for by Tennessee law.
The Company also maintains liability insurance for directors and officers, as authorized by the Act.
Item 7. Exemption from Registration Claimed.
Not applicable.
3
Item 8. Exhibits.
|
|
|
|
|
Exhibit No. |
|
Description |
|
4.1 |
|
|
Second Amended and Restated Charter of King Pharmaceuticals, Inc. (previously
filed as Exhibit 3.1(a) to the Companys Registration Statement No. 333-38753 on Form
S-1 filed with the Commission on October 24, 1997, and incorporated herein by
reference). |
|
|
|
|
|
|
4.2 |
|
|
Amended and Restated Bylaws of King Pharmaceuticals, Inc. (previously filed as
Exhibit 3.2(a) to the Companys Registration Statement No. 333-38753 on Form S-1 filed
with the Commission on October 24, 1997, and incorporated herein by reference). |
|
|
|
|
|
|
4.3 |
|
|
King Pharmaceuticals, Inc.s Incentive Plan (previously filed as Appendix B to
the Companys Definitive Proxy Statement, dated April 28, 2005, relating to its 2005
annual meeting of shareholders, and incorporated herein by reference). |
|
|
|
|
|
|
4.4 |
|
|
Rights Agreement (previously filed as Exhibit 99.1 to the Companys
Registration Statement on Form 8-A/A filed with the Commission on July 26, 2004, and
incorporated herein by reference). |
|
|
|
|
|
|
5.1 |
|
|
Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. as to the
legality of the shares being registered. |
|
|
|
|
|
|
23.1 |
|
|
Consent of PricewaterhouseCoopers, LLP. |
|
|
|
|
|
|
23.2 |
|
|
Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in
Exhibit 5.1 to the Registration Statement.). |
|
|
|
|
|
|
24.1 |
|
|
Power of Attorney (included with signatures). |
Item 9. Undertakings.
(a) The undersigned Registrant hereby undertakes :
(1) To file, during any period in which offers or sales are being made, a post-effective
amendment to the Registration Statement:
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of
1933 (the Securities Act);
(ii) To reflect in the prospectus any facts or events arising after the effective
date of this registration statement (or the most recent post-effective amendment thereof)
which, individually or in the aggregate, represent a fundamental change in the information
set forth in this registration statement. Notwithstanding the foregoing, any increase or
decrease in volume of securities offered (if the total dollar value of the securities
offered would not exceed what was registered) and any deviation from the low or high end
of the estimated maximum offering range may be reflected in the form of a prospectus filed
with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than a 20 percent change in the maximum aggregate offering
price set forth in the Calculation of Registration Fee table in the effective
registration statement;
(iii) To include any material information with respect to the plan of distribution
not previously disclosed in this registration statement or any material change to such
information in this registration statement;
provided, however, that sections (a)(1)(i) and (a)(1)(ii) do not apply if the
information required to be included in a post-effective amendment by those paragraphs is
contained in periodic reports filed with or furnished to the Commission by the Registrant
pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 (the Exchange
Act) that are incorporated by reference in this registration statement;
(2) That, for the purpose of determining any liability under the Securities Act, each such
post-effective amendment shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to
be the initial bona fide offering thereof; and
4
(3) To remove from registration by means of a post-effective amendment any of the
securities being registered which remain unsold at the termination of this offering.
(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability
under the Securities Act, each filing of the Registrants annual report pursuant to Section 13(a)
or Section 15(d) of the Exchange Act that is incorporated by reference in this registration
statement shall be deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof.
(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to
directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions,
or otherwise, the Registrant has been advised that in the opinion of the Commission such
indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by
the Registrant of expenses incurred or paid by a director, officer or controlling person of the
Registrant in the successful defense of any action, suit, or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being registered, the
Registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Act and will be governed by the final
adjudication of such issue.
5
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it
has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and
has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Bristol, State of
Tennessee, on this 6th day of
September 2005.
|
|
|
|
|
|
KING PHARMACEUTICALS, INC.
|
|
|
By: |
/s/ Brian A. Markison
|
|
|
|
Brian A. Markison |
|
|
|
President and Chief Executive Officer |
|
|
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS that the undersigned officers and directors of King
Pharmaceuticals, Inc., a Tennessee corporation, hereby constitute and appoint Brian A. Markison and
Ted G. Wood the true and lawful agents and attorneys-in-fact, with all power of substitution and
resubstitution, to sign for the undersigned, in their respective names as officers and directors of
the Corporation, one or more registration statements on Form S-8 (or other appropriate form) to be
filed with the Securities and Exchange Commission, Washington, D.C., under the Securities Act of
1933, as amended, and any amendment or supplement to such registration statement, relating to the
King Pharmaceuticals, Inc. Incentive Plan; hereby ratifying and confirming all acts taken by such
agent and attorney-in-fact as herein authorized.
Pursuant to the requirements of the Securities Act of 1933, as amended, this registration
statement has been signed by the following persons in the capacities indicated, and as of the date
first written above.
|
|
|
Signature |
|
Title |
|
/s/ Brian A. Markison
Brian A. Markison |
|
President, Chief Executive Officer and Director
(principal executive officer) |
/s/ Joseph Squicciarino
Joseph Squicciarino |
|
Chief Financial Officer (principal financial officer) |
/s/ Ted G. Wood
Ted G. Wood |
|
Non-Executive Chairman of the Board, Director |
/s/ Earnest W. Deavenport, Jr.
Earnest W. Deavenport, Jr. |
|
Director |
/s/ Elizabeth M. Greetham
Elizabeth M. Greetham |
|
Director |
/s/ Gregory D. Jordan
Gregory D. Jordan |
|
Director |
/s/ R. Charles Moyer
R. Charles Moyer |
|
Director |
/s/ Philip M. Pfeffer
Philip M. Pfeffer |
|
Director |
/s/ D. Greg Rooker
D. Greg Rooker |
|
Director |
6